长春高新：子公司GenSci134注射液境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech's subsidiary, GenSci, has received approval for the clinical trial application of GenSci134 injection for domestic production, which is aimed at treating children with growth retardation due to endogenous growth hormone deficiency [1] Group 1: Company Developments - The clinical trial application for GenSci134 injection has been approved by the National Medical Products Administration [1] - The drug is classified as a Class 1 therapeutic biological product and is intended for children with growth issues [1] - GenSci134 has previously been approved for clinical trials in adults with growth hormone deficiency, indicating a potential expansion of its application [1] Group 2: Industry Implications - Successful progress in the clinical trials could help the company diversify its business structure and enhance its core competitiveness [1] - The development of pharmaceutical products is inherently uncertain, and there are risks associated with the clinical trial process [1]